Cytomos unveils AuraCyt digital cell analytics platform at BIO 2026 to transform predictive bioprocessing
AI-driven cell analysis platform delivers earlier insights for bioprocessing and manufacturing
24 Jun 2026Product news
TechBio company Cytomos is unveiling its flagship cell analytic intelligence platform AuraCyt® and its novel benchtop technology Celledonia® at the BIO International Convention (BIO 2026) in San Diego, CA.
At its pod in the BIO Business Forum Zone D (Exhibit Hall 2221 UK Pavilion), Cytomos will demonstrate how its new digital platform enables earlier, smarter bioprocessing decisions by delivering rapid, label-free, predictive cell analytics for biomanufacturing and cell therapy development.
Addressing critical challenges in bioprocessing
Bioprocessing teams currently face slow, label-dependent analytical methods that are difficult to scale and offer limited predictive insight into cell behaviour. These constraints can delay process development, increase costs, and restrict the ability to optimise manufacturing workflows.
The Cytomos AuraCyt® platform has been developed to overcome these challenges by unlocking the power of predictive cell intelligence. By measuring intrinsic cell physics, AuraCyt® generates AI-ready digital fingerprints that reveal the true multi-dimensional state and behavior of individual cells.
How the AuraCyt platform works
The showcase benchtop cell analytics intelligence system combines the compact Celledonia® analyzer with the precision silicon sensors of the AuraCyt® modules. Together, they power the AuraCyt® Analysis Suite, which transforms complex cellular data into actionable insights for process scientists and manufacturing teams.
This rapid, label-free, single-cell analysis system predicts future productivity, stability and manufacturability. It enables earlier insights and real-time decision-making, lowers risk, provides scalable impact, optimises process performance and improves product consistency across a range of bioprocessing applications.
Demonstrated impact across key applications
Cytomos reports that its technology delivers measurable value across multiple use cases in biomanufacturing and cell therapy workflows. Example benefits include:
- Reducing cell line development (CLD) timelines by up to 40%
- Saving up to 65% of resources in lentivirus batch production
- Reducing CAR-T process time by up to 30%
By providing predictive insight into how cells will behave during processing, the AuraCyt® platform supports more efficient development and scale-up of advanced therapies and biologics.
Strategic partnerships and quality by design
Cytomos continues to engage with strategic partners to integrate its revolutionary technology into existing workflows, helping accelerate drug discovery, drug development and scale-up across multiple biomanufacturing arenas.
The company also emphasises innovation with quality by design, underlined by the recent ISO 9001 certification of Cytomos with zero non-conformances. This achievement reinforces Cytomos as a trusted partner in the life sciences sector, supporting organizations that require robust, reproducible and regulatory-aligned analytical solutions.
Cytomos Executive Chair, Alan Raymond, commented, “Our customers, partners and investors can be confident that Cytomos operates to the highest international standards. This is not just a badge – it’s a reflection of our mission to deliver reliable, reproducible, and meaningful results in cell analysis."
"Integrating our ground-breaking Auracyt® platform into existing workflows will transform bioprocessing and manufacturing, by detecting cell features for which there are no current biomarkers and providing predictive insights into how those cells will behave during processing. In short, it lets you see what’s coming — before it happens.”
To achieve this, Cytomos works closely alongside partners to integrate its pioneering technology into existing processes via a dedicated team of scientists and data analysts. These experts collaborate with multiple teams to make the AuraCyt® cell analytic intelligence systems both accessible and impactful across diverse bioprocessing environments.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does Cytomos’ AuraCyt platform improve bioprocessing and cell therapy development?
AuraCyt® enhances bioprocessing and cell therapy development by delivering rapid, label-free, single-cell analytics that measure intrinsic cell physics. The platform generates AI-ready digital fingerprints to predict future productivity, stability and manufacturability. This enables earlier insights, real-time decision-making, reduced risk, scalable impact, optimized process performance and improved product consistency across biomanufacturing and cell therapy workflows.
What benefits has Cytomos demonstrated for biomanufacturing and CAR-T cell therapy workflows?
Cytomos reports measurable value across multiple bioprocessing applications. The AuraCyt® platform can reduce cell line development timelines by up to 40%, save up to 65% of resources in lentivirus batch production, and reduce CAR-T process time by up to 30%. These predictive cell analytics support more efficient development and scale-up of advanced therapies and biologics in biomanufacturing and cell therapy.
Where will Cytomos showcase AuraCyt and Celledonia at BIO International Convention 2026?
Cytomos will unveil its AuraCyt® cell analytic intelligence platform and Celledonia® benchtop technology at BIO International Convention 2026 in San Diego, CA. The company will demonstrate its predictive cell analytics at its pod in the BIO Business Forum Zone D, Exhibit Hall 2221, within the UK Pavilion.